Curis Dirección
Dirección controles de criterios 3/4
El CEO de Curis es Jim Dentzer , nombrado en Sep 2018, tiene una permanencia de 7.83 años. compensación anual total es $1.66M, compuesta por 40.5% salario y 59.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $35.97K. La antigüedad media del equipo directivo y de la junta directiva es de 5.9 años y 12 años, respectivamente.
Información clave
Jim Dentzer
Chief Executive Officer (CEO)
US$1.7m
Compensación total
| Porcentaje del salario del CEO | 40.50% |
| Permanencia del CEO | 7.8yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 5.9yrs |
| Promedio de permanencia en la Junta Directiva | 12yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jul 06
CRIS: TakeAim CLL Progress Will Reshape Perceived Risk Profile
Analysts have sharply increased their price target on Curis to $400 from $20, citing a lower assumed discount rate, higher projected revenue growth, modestly stronger profit margins, and a slightly higher future P/E multiple as the key factors behind the updated view. Analyst Commentary on Curis Recent research updates on Curis signal a clear shift toward a more constructive stance, with bullish analysts pointing to a mix of valuation reset, growth potential, and improving execution as reasons to revisit the stock.Artículo de análisis • Jul 01
Curis (NASDAQ:CRIS) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Actualización de narrativa • Jun 22
CRIS: Future Profitability Execution Will Support Maintained 14 Fair Value
Analysts maintained their $14.00 price target for Curis, citing updated assumptions that combine a lower discount rate with higher projected revenue growth, wider profit margins and a slightly higher future P/E multiple as the main factors behind the refreshed valuation work. Analyst Commentary Recent commentary on Curis centers on how the refreshed $14.00 valuation stacks up against execution risk, profitability assumptions and the path to monetizing the company’s pipeline.
Actualización de narrativa • Jun 05
CRIS: Expanded Share Authorization And Lower P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Curis, citing updated assumptions that now include a slightly lower discount rate, a smaller expected revenue decline, a modestly higher profit margin, and a much lower future P/E multiple to support the change. Analyst Commentary Recent research on Curis points to a mixed backdrop, where some price target adjustments sit alongside a cautious tone on execution and valuation risk.Actualización de narrativa • May 11
CRIS: Expanded Share Authorization Will Support Future Upside Despite Delisting Risks
Analysts raised their price target on Curis by $5, citing updated assumptions for revenue decline, improved profit margin expectations, a slightly lower discount rate, and a reduced future P/E estimate. Analyst Commentary Analyst reactions around Curis highlight a mix of higher price targets and upgraded ratings, but also a thread of caution around how much upside is already reflected in the stock and how execution risk could affect valuation.Actualización de narrativa • Apr 24
CRIS: Expanded Share Authorization And Elevated Future P/E Will Support Upside
Analysts have raised the price target on Curis to $5.00 from $5.00, citing updated assumptions around discount rates, slightly less severe expected revenue contraction, lower profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on peer names in the broader consumer space highlights how quickly sentiment can shift when expectations around earnings power, tariff exposure, and valuation multiples come under scrutiny.Actualización de narrativa • Apr 09
CRIS: Expanded Capital Base And Elevated Future P/E Will Support Upside
Analysts have adjusted their price target on Curis to $5.00 from $5.00, citing slightly lower discount rate and revenue decline assumptions, along with a higher future P/E multiple, as key drivers of the updated view. Analyst Commentary Bearish analysts looking at Curis are focusing on how the current valuation lines up with execution risk and the assumptions baked into the updated price target.Actualización de narrativa • Mar 26
CRIS: Expanded Capital Base And Rich Future P/E Will Support Upside
The analyst price target for Curis has been adjusted from $5 to $5.00. Analysts cite a lower discount rate, a shift to expectations of a 15.61% revenue decline, and a significantly higher assumed future P/E multiple as the main factors behind this revision.Actualización de narrativa • Mar 11
CRIS: Maintained US$14 Fair Value Will Depend On Execution Risk
Analysts have maintained their $14.00 price target on Curis while adjusting key inputs, including a slightly lower discount rate, a revised profit margin outlook, and a higher future P/E assumption to reflect updated views on execution risk and valuation support. Analyst Commentary Analysts covering Curis are focusing less on big headline calls and more on how the updated assumptions behind the $14.00 price target line up with execution risk, profitability, and valuation support.Actualización de narrativa • Feb 24
CRIS: Expanded Capital Base And Financing Structure Will Support Long-Term Upside
Narrative update on Curis The analyst price target for Curis has been lifted by $7, with analysts pointing to a slightly lower discount rate, modestly higher revenue growth expectations and a somewhat richer future P/E assumption as key drivers of the change. Analyst Commentary Recent Street research around comparable names highlights how quickly sentiment can swing when execution, growth visibility, or valuation do not line up cleanly.Actualización de narrativa • Feb 10
CRIS: Maintained US$14 Fair Value Will Rely On Clinical Progress
Analysts have kept their price target for Curis steady at US$14.00. The updated view reflects slightly lower discount rate and profit margin assumptions, which are offset by a modestly reduced future P/E multiple.Actualización de narrativa • Jan 25
CRIS: Frontline AML Data And Insider-Backed Financing Will Support Long-Term Upside
Analysts have lifted their price target on Curis to $5.00 from $5.00, citing updated assumptions around higher projected revenue growth and slightly stronger long-term profit margins, partially tempered by a higher discount rate and a lower future P/E multiple. Analyst Commentary Recent Street research on other consumer names highlights several themes that cautious investors are watching closely and that can be relevant when you think about Curis as well.Actualización de narrativa • Jan 10
CRIS: Higher Future P/E And Clinical Progress Will Support Long Term Earnings
Analysts have raised their price target on Curis to $14.00, a change they link to updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple. Analyst Commentary Analysts are applying a similar playbook across several consumer names, and that context helps explain the recent price target move on Curis.Artículo de análisis • Jan 04
Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 27% in the last thirty days...Actualización de narrativa • Dec 25
CRIS: Frontline AML Data Will Drive Long-Term Upside Despite Heightened Risk
Analysts have cut their price target on Curis from $12.00 to $5.00 as they increase the assumed discount rate, while also lifting revenue growth expectations and lowering future valuation multiples. This reflects a more cautious yet still constructive outlook on the company’s long-term earnings power.Actualización de narrativa • Dec 11
CRIS: Reduced Risk Profile Will Support Long Term Earnings Recovery
Analysts have nudged their price target on Curis modestly higher to $14.00, citing slightly lower perceived risk and a marginally cheaper future earnings multiple. Together, these factors support a cautiously more constructive long term outlook.Actualización de narrativa • Nov 27
CRIS: Cost Efficiencies Will Drive Earnings Recovery Despite Macro Pressures
Curis's analyst price target has been raised modestly, with analysts citing improved profit margin projections and a better cost outlook as reasons for the updated valuation of $14.00 per share. Analyst Commentary Analysts recently updated their perspectives on Curis in light of the company’s latest performance and forward-looking guidance.Artículo de análisis • Nov 20
Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 28...Actualización de narrativa • Nov 13
CRIS: Cost-Saving Initiatives Will Support Stronger Revenue Expansion Into 2026
Curis's analyst price target has been reduced from $16.33 to $14.00. This adjustment reflects analysts' concerns over softer profit margins, even with stronger revenue growth projections and an increased discount rate.Artículo de análisis • Aug 08
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
NasdaqCM:CRIS 1 Year Share Price vs Fair Value Explore Curis's Fair Values from the Community and select yours Curis...
Nueva narrativa • Apr 14
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.Artículo de análisis • Apr 02
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Celebrations may be in order for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the analysts delivering a significant...Artículo de análisis • Apr 01
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 30...Artículo de análisis • Dec 29
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 26% in the last thirty days...Artículo de análisis • Nov 14
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Curis, Inc. ( NASDAQ:CRIS ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Aug 07
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Curis, Inc. ( NASDAQ:CRIS ) shareholders will have a reason to smile today, with the analysts making substantial...Artículo de análisis • Aug 05
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 2.9x Curis, Inc. ( NASDAQ:CRIS ) may be sending very bullish signals at the...Artículo de análisis • Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Curis, Inc. ( NASDAQ:CRIS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Artículo de análisis • Dec 26
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Curis, Inc. ( NASDAQ:CRIS ) shareholders have had their patience rewarded with a 63% share price jump in the last...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$21m |
| Dec 31 2025 | US$2m | US$672k | -US$8m |
| Sep 30 2025 | n/a | n/a | -US$37m |
| Jun 30 2025 | n/a | n/a | -US$39m |
| Mar 31 2025 | n/a | n/a | -US$42m |
| Dec 31 2024 | US$2m | US$653k | -US$43m |
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$2m | US$634k | -US$47m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$3m | US$615k | -US$57m |
| Sep 30 2022 | n/a | n/a | -US$59m |
| Jun 30 2022 | n/a | n/a | -US$57m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$3m | US$590k | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$545k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$510k | -US$32m |
Compensación vs. Mercado: La compensación total de Jim($USD1.66M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD658.00K).
Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.
CEO
Jim Dentzer (59 yo)
7.8yrs
Permanencia
US$1,659,756
Compensación
Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.8yrs | US$1.66m | 0.37% $ 36.0k | |
| CFO and Principal Financial & Accounting Officer | 3.9yrs | US$925.23k | 0.19% $ 18.8k | |
| Chief Development Officer | 3.2yrs | US$932.30k | 0.17% $ 16.1k | |
| Vice President of Technology Management & Intellectual Property | 17.8yrs | US$413.39k | sin datos | |
| VP & General Counsel | no data | sin datos | sin datos | |
| Senior Director of Human Resources | no data | sin datos | sin datos | |
| Chief Medical Officer | no data | sin datos | 0.17% $ 16.1k |
5.9yrs
Permanencia media
61yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRIS es experimentado (5.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.8yrs | US$1.66m | 0.37% $ 36.0k | |
| Independent Chairman of the Board | 26.4yrs | US$134.45k | 0.0032% $ 314.2 | |
| Independent Director | 16.1yrs | US$99.45k | 0.070% $ 6.8k | |
| Independent Director | 22.7yrs | US$101.95k | 0.029% $ 2.8k | |
| Independent Director | 4.6yrs | US$81.95k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$79.45k | 0% $ 0 | |
| Member of AML & MDS Advisory Board | no data | sin datos | sin datos | |
| Member of AML & MDS Advisory Board | no data | sin datos | sin datos | |
| Member of AML & MDS Advisory Board | no data | sin datos | sin datos | |
| Member of Lymphoma Advisory Board | no data | sin datos | sin datos | |
| Member of Lymphoma Advisory Board | no data | sin datos | sin datos | |
| Member of AML & MDS Advisory Board | no data | sin datos | sin datos |
12.0yrs
Permanencia media
68.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CRIS son experimentados ( 12 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/10 07:09 |
| Precio de las acciones al final del día | 2026/07/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Curis, Inc. está cubierta por 17 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |